| Literature DB >> 35093121 |
Marjan Talebi1, Seyyed Ali Mohammadi Vadoud2, Alireza Haratian1, Mohsen Talebi3,4, Tahereh Farkhondeh5,6, Ali Mohammad Pourbagher-Shahri5, Saeed Samarghandian7.
Abstract
Regarding the epidemiological studies, neurological dysfunctions caused by cerebral ischemia or neurodegenerative diseases (NDDs) have been considered a pointed matter. Mount-up shreds of evidence support that both autophagy and reactive oxygen species (ROS) are involved in the commencement and progression of neurological diseases. Remarkably, oxidative stress prompted by an increase of ROS threatens cerebral integrity and improves the severity of other pathogenic agents such as mitochondrial damage in neuronal disturbances. Autophagy is anticipated as a cellular defending mode to combat cytotoxic substances and damage. The recent document proposes that the interrelation of autophagy and ROS creates a crucial function in controlling neuronal homeostasis. This review aims to overview the cross-talk among autophagy and oxidative stress and its molecular mechanisms in various neurological diseases to prepare new perceptions into a new treatment for neurological disorders. Furthermore, natural/synthetic agents entailed in modulation/regulation of this ambitious cross-talk are described.Entities:
Keywords: Autophagy; Neurodegenerative diseases; Neurological diseases; Oxidative stress; Signaling pathways, Alzheimer’s disease, Parkinson’s disease, Reactive Oxygen Species (ROS)
Mesh:
Substances:
Year: 2022 PMID: 35093121 PMCID: PMC8799983 DOI: 10.1186/s12993-022-00187-3
Source DB: PubMed Journal: Behav Brain Funct ISSN: 1744-9081 Impact factor: 3.759
Fig. 1The interplay between ROS and autophagy. ROS can be induced following various triggers entailing hypoxia, starvation, and mitophagy. Afterward excessive production of ROS, some factors are affected comprising HIF-1α, AMPK, JNK, and Nrf2/Keap1. Alongside these biological circumstances, autophagy may be inhibited/activated by forming the ULK complex, PI3K complex, and mTORC1 complex. Important factors involved in autophagy are LC3II and p62
Summary of compounds involved in regulation (activation or inactivation) of autophagy process of neurological diseases
| Neurological disease | Therapeutic compound | Species/cell lines | Primary contributed mechanisms related to autophagy | Refs |
|---|---|---|---|---|
| Alzheimer’s disease | Lithium | Various models | Regulation of inositol monophosphatase, GSK-3β, and mTOR | [ |
| Hydroxyurea | APP/PS1 mice | Augmentation of the expression of LC3 | [ | |
| Atorvastatin | Aβ1–42- SH-SY5Y | Elevation of the expression of sestrins and LC3-II, alleviation of sirtuins and TPP1 | [ | |
| Ferric-Tannic nanoparticles | In vitro | activation of lysosome | [ | |
| Curcumin | APP/PS1 double transgenic AD mice | Inhibition of PI3K/Akt/mTOR, an increase of LC3I/II and Beclin1 expression | [ | |
| Berberine | Three × Tg-AD mice | Augmentation of LC3-II, Beclin-1, hVps34, and Cathepsin-D | [ | |
| Berberine and Curcumin | Aβ1-42-AD mice | Augmentation of AMPKα phosphorylation and cell autophagy | [ | |
| Resveratrol | Aβ1–42-induced AD-PC12 | Activation of mitophagy due to the abrogation of oxidative stress | [ | |
| Geniposide | APP/PS1 mice | downregulation of mTOR | [ | |
| Polydatin | Aβ-induced neuron cytotoxicity | activation of AMPK/mTOR pathway | [ | |
| Melatonin | AAV-hTauP301L viral vectors and okadaic acid-Tauopathy, mice and human brain tissue | improvement of the autophagy markers comprising p62, LAMP1, and LC3 | [ | |
| α-Tocopherol | Aβ-SH-SY5Y | Regulation of cathepsin-B, -L, -D, syntaxin 17, GABA type A receptor-associated protein, GABA type A receptor-associated protein-like 1; ATG3, ATG4A, ATG4B, myotubularin related protein 3, UV radiation resistance-associated, autophagy and Beclin 1 regulator 1, vacuole membrane protein 1, WDrepeat domain, phosphoinositide interacting 1, WDrepeat domain, phosphoinositide interacting 2, unc-51 like autophagy activating kinase 2 | [ | |
| Oleuropein aglycone | Aβ-AD mice, SH-SY5Y | Induction of AMPK/ULK1, inhibition of mTOR | [ | |
| Garcinol | Acrylamide-brain of zebrafish larvae | Regulation of cathepsin-B | [ | |
| Carnosic acid | Aβ 1–42- SH-SY5Y | Increase LC3-II/I ratio, decrease SQSTM1(p62) | [ | |
| β-asarone | Aβ, PC12 cells | Alleviation of autophagy occurred via Akt/mTOR signaling pathway | [ | |
| Euxanthone | Aβ1-42-PC12 | Augmentation of LC3-II and Beclin1, alleviation of p62 | [ | |
| Oleocanthal | TgSwDI mice | Activation of AMPK/ ULK1 pathway | [ | |
| MPTP-induced PD in mice | Elevation of NIX expression, decrease of LC3-II/LC3-I ratio, regulation of AMPK, mTOR, and ULK1 | [ | ||
| Parkinson’s disease | Metformin | In vitro and in vivo | Activation of AMPK and inhibition of α-synuclein | [ |
| Sulforaphane | Rotenone-mice, SH-SY5Y | Decrease expression of LC3-II | [ | |
| Morphine (low dose) | 6-OHDA-SH-SY5Y and rats | Augmentation of LC3-II, alleviation of p62 | [ | |
| Manganese nanoparticle | N27 dopaminergic neuronal cells | Improvement of Beclin 1 and LC3 | [ | |
| α-Arbutin | Rotenone-induced PD, SH-SY5Y, drosophila | Modulation of AMPK/p62 | [ | |
| Polydatin | Rotenone or Parkin deficiency-SH-SY5Y | Promotion of ATG5 in a parkin-independent autophagy manner | [ | |
| Glycyrrhizic acid | 6-OHDA and corticosterone-induced PD in SH-SY5Y | Attenuation of α-Syn and p-S1292-LRRK2 proteins expression, upregulation of LC3B II/I and Beclin-1 | [ | |
| α-lipoic acid | 6-OHDA-SH-SY5Y cells | blockade AMPK/mTOR signaling pathway | [ | |
| Icariin | Rotenone-PC12 cells | Regulation of LC3-II, Beclin1, p62 | [ | |
| β-amyrin | 6-OHDA- | Regulation of LGG-1 | [ | |
| kaempferol | Rotenone- SH-SY5Y | Increase the expression of LC3-II | [ | |
| Huntington’s disease | Tolfenamic acid | transgenic R6/1 mice | Increase LC3-II/LC3-I ratio, decrease expression of p62 | [ |
| Liraglutide | mHTT- SK-N-MC cells | Upregulation of the phosphorylation of Thr172-AMPK and LC3-II | [ | |
| Trehalose | skin biopsies of HD patients | Increase LC3 and LAMP2-A levels | [ | |
| Resveratrol | polyQ-Htt- SH-SY5Y | restoring ATG4 level, allowing the LC3 lipidation, facilitating polyQ-Htt degradation | [ | |
| Rutin | Autophagy by activation of protein degradation | [ | ||
| Amyotrophic lateral sclerosis | Riluzole | HeLa cells | Increase the amount of HSF1 regarding the chaperone-mediated autophagy | [ |
| p-Coumaric Acid | SOD1mut- N2a cells | increased the level of LC3-II, decrease the protein level of p62 | [ | |
| Cerebral ischemia | Ulinastatin | A variety of models | Inhibition of neuronal autophagy | [ |
| Tanshinone IIA | OGD/R- HT-22 cells | Activation of PI3K/Akt/mTOR pathway | [ | |
| Resveratrol | cerebral ischemia rats | Increase expression of LC3II | [ | |
| Gabapentin | middle cerebral artery occlusion-rats | Regulation of the PI3K/Akt/mTOR signaling pathway | [ | |
| Melatonin | I/R-rats, OGD/R-PC12 cells | Reduction of LC3II/LC3I, an increase of p62 | [ | |
| OGD/R- primary hippocampal neurons | Activation of PI3K/Akt/mTOR pathway | [ | ||
| Tetrahydroxystilbene glucoside | middle cerebral artery occlusion-mice | Elevation of Beclin 1 and the LC3BII/I ratio | [ | |
| Shengmai | Cerebral I/R injury-mice | modulation of the AMPK, mTOR, and JNK pathways, inhibition of Beclin1 and LC3 | [ | |
| Esculetin | transient bilateral typical carotid artery occlusion -treated mice | Regulation of Bnip3, Beclin1, Pink1, parkin, and the LC-3 II/I ratio | [ | |
| Luteolin | MCAO rat model | Regulation of SIRT3/AMPK/mTOR Signaling Pathway | [ | |
| Chronic Cerebral Hypoperfusion | Resveratrol | CCH-rats | Regulation of AKT/mTOR Signaling | [ |
| Spinal Cord Injury | Omega-3 fatty acids | Rodent models | Increase of LC3-II expression, reduction of p38 MAPK expression | [ |
| Calcitriol | laminectomy and spinal cord compression injury-rats | Augmentation of LC3-II and Beclin1, alleviation of p62 | [ | |
| Spinocerebellar ataxia | Caffeic acid and resveratrol | mutant ataxin-3-SK-N-SH-MJD78 cells, Drosophila | Upregulation of p62 expression | [ |
| lactulose and melibiose | SCA3 ATXN3/Q75-GFP cell model | Regulation of autophagy | [ | |
| Neurotoxicity | Methylone and MDPV | β-keto amphetamines-SH-SY5Y cells | Increase expression of LC3-II | [ |
Fig. 2The interplay between autophagy and oxidative stress in Alzheimer’s disease. AD condiiton is acompained by increase in LC and inhibition of p62 expersions that inhibit the NFKB, Nrf2 and cAMP but increase ROS production
Fig. 3A variety of autophagy implications are exhibited in this figure. Activation/inhibition of autophagy and its related genes can contribute to neurological disorders, various cancers, cardiometabolic diseases, pulmonary conditions, aging, autoimmune disease, bone, skeletal muscle diseases, eye disease, congenital developmental disorders, and infections, inflammatory maladies, liver, and renal disease